In cell and gene therapy development, everything begins with the starting material — the raw cellular input that ultimately becomes the therapeutic product. Whether you're working with patient-derived cells, donor cells, or engineered lines, the genomic integrity of your starting material directly impacts product quality, safety, and regulatory success.
The KROMASURE™ Platform provides a powerful suite of tools for deep, single-cell structural and copy number analysis of starting material, delivering a critical layer of insight before manufacturing even begins. By identifying genomic abnormalities early, developers can make better decisions, reduce downstream risk, and build a stronger foundation for the entire product lifecycle.
Why Starting Material Genomics Matter
Starting material isn't just the beginning — it's the blueprint. Structural genomic issues like chromosomal translocations, aneuploidy, or undetected deletions can:
-
Compromise cell function or viability
-
Skew experimental outcomes
-
Undermine gene editing precision
-
Raise red flags during regulatory review
Yet traditional methods like karyotyping or bulk sequencing miss low-frequency and cell-specific events, leaving blind spots in the very cells you're building on.
KROMASURE™: Single-Cell Clarity from Day One
The KROMASURE™ Platform delivers non-metaphase, high-resolution genomic insight at the single-cell level, making it ideal for analyzing diverse starting material types, including:
-
Hematopoietic stem cells
-
T cells
-
iPSCs
-
Primary hepatocytes
-
Immortalized lines
With the ability to assess thousands of cells in a single run, KROMASURE™ gives you a statistically robust understanding of your starting population's structural stability, ploidy, and overall genomic integrity.
Key Benefits of KROMASURE™ for Starting Material
🔍 Detect Hidden Genomic Abnormalities
-
Identify balanced/unbalanced translocations, aneuploidy, and deletions with high specificity
-
Go beyond karyotyping with detection limits down to just a few kilobases
🧬 Ensure Genome Integrity Pre-Editing
-
Screen for baseline abnormalities before genome engineering begins
-
Reduce confounding factors in editing efficiency and outcome variability
📊 Population-Level Insight with Single-Cell Resolution
-
Understand heterogeneity within your starting material
-
Detect subclonal events that bulk sequencing averages out
⚠️ De-Risk Regulatory Pathways
-
Generate data suitable for regulatory submission, strengthening the rationale for cell selection and QC
-
Support risk assessment models with high-confidence genomic evidence
Integrated, Scalable, and Ready to Go
KROMASURE™ is optimized for interphase analysis, eliminating the need for metaphase prep and reducing turnaround time. It integrates seamlessly with other KROMATID solutions like PinPoint™ and InSite for a full-spectrum structural genomic view — from starting material to final product.
Better Inputs. Better Outcomes.
Starting material analysis is no longer optional — it’s a critical control point in the development of safe, effective cell and gene therapies. With the KROMASURE™ Platform, you gain unprecedented visibility into the genomic quality of your starting cells, empowering better science, smarter decisions, and stronger regulatory submissions.
Start smart. Start with KROMASURE™.